July 17, 2025

FDA Approves RSV Shot Despite High Infant Risk - AI Podcast

8 minutes

Story at-a-glance

Merck’s respiratory syncytial virus (RSV) shot clesrovimab (Enflonsia) was approved even though 11.71% of babies in the trial experienced serious adverse events, including seizures, brain injury, and death
Infants who got clesrovimab had a 350% higher risk of upper respiratory infections — exactly the type of illness this shot claims to prevent
The injection is given in a single, fixed dose regardless of infant weight, putting smaller, younger babies at greater risk due to disproportionately high exposure
Babies who received the shot had a threefold increase in severe neurological reactions compared to those given a placebo
Only about 25 babies in the U.S. succumb to RSV each year, making the known risks of clesrovimab far outweigh the threat the virus poses to most children

...more

By Dr. Mercola

4.6

14631,463 ratings

July 17, 2025

8 minutes

Story at-a-glance

Merck’s respiratory syncytial virus (RSV) shot clesrovimab (Enflonsia) was approved even though 11.71% of babies in the trial experienced serious adverse events, including seizures, brain injury, and death
Infants who got clesrovimab had a 350% higher risk of upper respiratory infections — exactly the type of illness this shot claims to prevent
The injection is given in a single, fixed dose regardless of infant weight, putting smaller, younger babies at greater risk due to disproportionately high exposure
Babies who received the shot had a threefold increase in severe neurological reactions compared to those given a placebo
Only about 25 babies in the U.S. succumb to RSV each year, making the known risks of clesrovimab far outweigh the threat the virus poses to most children

...more